ESMO Open - TopPodcast.com

View Top 200 Chart

Back to Rankings Page

ESMO Open — Health & Fitness
ESMO Open

ESMO Open is the European Society for Medical Oncology’s online-only, peer-reviewed Open Access journal, dedicated to publishing high-quality medical research and educational content from all disciplines of oncology, with a focus on innovative clinical and translational cancer research.
The journal is published by BMJ on behalf of ESMO.
http://esmoopen.bmj.com/
* The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.

Copyright: © 643134

Latest Episodes:

ASCO - Practice changing studies in gastrointestinal cancer Apr 04, 2017

Show notes

In this podcast new, practice-changing research in gastrointestinal (GI) cancer is considered. Clinical trials focusing on immunotherapies presented at the recent ASCO Gastrointestinal Cancers Symposium in San Francisco are discussed. Highlights include reports of the ONO-4538 study, in which pretreated gastric cancer patients were randomized to receive either nivolumab or best supportive care, and of the CheckMate 040 study in which pretreated patients with hepatocellular carcinoma received nivolumab. Nivolumab is also assessed in the CheckMate 142 which considered patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer. Other new treatment options and combinations with immunotherapy are briefly considered, but the author suggests that it is too early to draw conclusions from these preliminary data. Emergent side effects from immunotherapy trials in GI cancer are also discussed. In closing the author considers developments in immunotherapy of GI cancers in the adjuvant setting but notes that trial results are still awaited. These highlights are presented by Professor Gerald Prager, Medizinische Universitat Wien, Department of Medicine, Vienna, Austria (gerald.prager@gmx.eu) and the interview is conducted by Anna Berghoff, Medical University of Vienna. http://esmoopen.bmj.com/

Read the abstract on the ESMO Open website: http://esmoopen.bmj.com/content/2/3/e000228.

New horizons in breast cancer therapy - ESMO congress, ASCO and San Antonio Symposium’s highlights Jan 27, 2017

Show notes

Elżbieta Senkus, Medical University of Gdansk, Department of Oncology and Radiotherapy, Gdańsk, Poland, (elsenkus@gumed.edu.pl) presents an overview of new therapies on the horizon for breast cancer in terms of data presented at the ESMO Congress, ASCO, and the San Antonio Breast Cancer Symposium. In the adjuvant setting, results from the MINDACT trial, which evaluated genomic versus clinical assessment for risk stratification, are described. Data on the role of anthracyclines in adjuvant chemotherapy is also discussed. In HER2-positive patients, dual HER2-targeted therapy was investigated in the KRISTINE study, and studies on the duration of adjuvant endocrine therapy in advanced breast cancer are also considered. Other ongoing studies in this population and the luminal population are also briefly mentioned. In the metastatic setting, the PALOMA-2 and MONALEESA-2 studies assessed the addition of CDK4/6 inhibitors to standard treatments. Results of the MONARCH 1 trial, evaluating a CDK4/6 inhibitor as a single agent, are also described, along with data on endocrine therapy in the luminal setting. Recent data on drugs interacting with the mTOR/PI3K/AKT pathway are considered. Studies in advanced HER-2 positive patients, considering HER-2 duel blockade plus either chemotherapy or endocrine therapy, are discussed. The situation in triple-negative breast cancer and advances and future directions in precision medicine and immunotherapy in breast cancer are briefly discussed.

Read the abstract on the ESMO Open website: http://esmoopen.bmj.com/content/2/2/e000204.

Tumor Network in Glioma Nov 08, 2016

Show notes

In this podcast a new biological insight in brain tumors is discussed by Frank Winkler, DKFZ, CCU Neurooncology, Heidelberg, Germany (f.winkler@dkfz.de). The author’s group has identified the existence of a tumor cell network in incurable gliomas which facilitates multicellular communication and exchange of small molecules between single tumor cells. The tumor cells that are integrated in this network, around 50% of cells according to studies in mouse models and patient samples, appear to be protected from the effects of radiotherapy and possibly also chemotherapy, which may explain how such tumors develop resistance to therapies and why patients relapse after treatment. An overview of ideas that are being investigated preclinically to therapeutically target this network of tumor cells is given. These include approaches to disrupt the network, such as obstructing cellular communication with gap junction blockers and targeting the neurodevelopmental pathways required to form the networks. Conversely, methods to exploit the network through the local application of gap-permeable drugs which specifically target the integrated tumor cells could also be studied. This new discovery may result in the development of therapeutic strategies which the author hopes will reach the clinic in the next few years.

Visit the ESMO Open website: http://esmoopen.bmj.com/content/1/6/e000133.

Highlights in breast cancer from ASCO 2016 Sep 15, 2016

Show notes

A critical review of the highlights in breast cancer research from the American Society of Clinical Oncology (ASCO) meeting 2016, held in June 2016 in Chicago, is presented in this podcast by Fatima Cardoso, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal (fatimacardoso@fundacaochampalimaud.pt). Considering the most interesting and practice-changing studies reported at the meeting, in the advanced breast cancer setting several important confirmatory studies on the use of CDK inhibitors, and studies on using data on estrogen receptor mutations to guide choices of endocrine therapy are discussed. The PHEREXA trial, in which a combination trastuzumab and pertuzumab was studied in the advanced setting is also considered. In the early breast cancer setting, the KRISTINE and ADAPT studies evaluated the potential of dual blockade in HER2-positive tumors. In HER2-negative early breast cancer several trials are also discussed with respect to types of adjuvant chemotherapy. The results of the MA.17R trial, which considered extending the duration of adjuvant endocrine therapy, are also discussed. The potential role of immunotherapy in breast cancer therapy is briefly mentioned.

The podcast is conducted by Anna Berghoff, Medical University of Vienna, Austria.

ASCO Highlights podcast: Head and neck cancers Jul 20, 2016

Show notes

These highlights are presented by Marco Merlano, Department of Medical Oncology, Santa Croce General Hospital, Cuneo, Italy,(mcmerlano@gmail.com). A critical review of the head and neck cancer research highlights of the American Society of Clinical Oncology (ASCO) meeting 2016, held in June 2016 in Chicago, is presented in this podcast. Considering the most interesting and practice-changing trials reported at the meeting, the key trial comparing gemcitabine plus cisplatin against 5-FU plus cisplatin in the treatment of nasopharyngeal carcinoma is highlighted. The GORTEC2007-02 trial comparing induction docetaxel/platinum/ 5-FU followed by cetuximab-radiotherapy against concurrent chemo-radiotherapy for N2b/c-N3 non operated stage III-IV squamous cell cancer of the head and neck is also discussed. An overview of the research reported using immunotherapy in head and neck cancer is also given, considering maturing data and particularly in relapsing patients, where response rates, though low, are better than with current therapies, and the responses are long lasting. Future developments are also considered, again with a focus on immunotherapy, but also considering combination with radiotherapy and chemoradiation. The podcast is conducted by Anna Berghoff, Medical University of Vienna

Vienna, Austria, and is also available on the ESMO Open website: http://esmoopen.bmj.com/content/1/5/e000099.

Highlights from the European Lung Cancer Conference (ELCC) 2016 May 10, 2016

Show notes

The highlights are presented by Rolf A. Stahel, Universitätsspital Zürich, Onkologie, Zürich, Switzerland (rolf.stahel@usz.ch). A critical review of the highlights of the European Lung Cancer Conference (ELCC) 2016, held in April 2016 in Geneva, is presented in this podcast. Considering the most interesting and practice-changing trials reported at the meeting, the key trial on the use of osimertinib in patients with non-small cell lung cancer (NSCLC) with EGFR harbouring the T790M mutation who had progressed on first line tyrosine-kinase inhibitors (TKIs) was highlighted. The meeting also featured interesting studies on testing for the T790M mutation and highlighted the potential of liquid biopsies. Two areas of potentially valuable biomarker development were stressed: biomarkers in oncogenic-driven NSCLC, and, more controversially, immunotherapy-related biomarkers. New treatment strategies were highlighted by the presentation of the Heine H. Hansen Award to Professor Suresh Senan (Amsterdam) whose work on stereotactic radiotherapy of lung cancer has led to significant changes in practice. Further, immunotherapy of lung cancer, through the use of immune-checkpoint inhibitors is already in clinical practice, and the results of ongoing trials considering whether immunotherapy can replace chemotherapy in these settings are now eagerly waited. The podcast is conducted by Anna Berghoff, Medical University of Vienna

Vienna, Austria.

The Cancer Genome - Highlights of a Nature Medicine Perspective Apr 11, 2016

Show notes

These highlights are presented by Emile Voest, The Netherlands Cancer Institute - Molecular Oncology, Amsterdam, Netherlands (e.voest@nki.nl). The author reviews the recently published article “Facilitating a Culture of Responsible and Effective Sharing of Cancer Genome Data” (Nat Med. 2016 May 5;22(5):464-71 - http://goo.gl/O3DRMf.) considering why data sharing is important and explaining the obstacles and problems involved. The need to identify common bioinformatics pipelines and resolve outstanding legal, ethical and technical issues are highlighted. Particular attention is given to emerging issues around informed consent and the handling of electronic patient records. There is a real need to address all these issues now on multiple levels in order to fulfil the promise of personalised medicine. The author further considers the work of the Global Alliance for Genomics and Health across cancer, rare diseases and in the emerging field of infectious diseases genomics. Finally, the potential impact of cancer genomic data on clinical practice is considered and the enormous potential for it to inform good decision making is underscored. The podcast is conducted by Anna Berghoff, Medical University of Vienna Vienna, Austria.

Visit the ESMO Open website: http://esmoopen.bmj.com/.

Highlights from the ESMO Symposium on Signalling Pathways in Cancer 2016 Apr 04, 2016

Show notes

A critical review of the highlights of the ESMO Symposium on Signalling Pathways in Cancer 2016, held March 2016 in partnership with the European Association of Cancer Research, is presented in this podcast. The meeting addressed developments in personalized medicine associated with the HER/EGFR family. Key subjects discussed were the bases of the mechanisms of signal transduction and primary and secondary resistance to EGFR-inhibiting drugs, and the emergence of better characterized subtypes of common tumors such as colorectal cancer, breast cancer, lung cancer and gastric cancer, and new utilities to effect these characterizations. Findings to consider include the increasing importance of tumor heterogeneity; the understanding that not all cells in a tumor have the same mutation may help develop new kinase inhibitors and new strategies. Further, data suggest that maintaining inhibition of the signaling process, even in the face of secondary resistance, can prolong clinical benefit. There is a need to develop new compounds that either bind more effectively to known EGFR mutations, or which can bind to newly identified mutations. The potential of both vertical and horizontal inhibition to achieve synergistic effects and so prolong tumor control was stressed.

The highlights are presented by Josep Tabernero, of the Vall d'Hebron Institute of Oncology - Medical Oncology, Barcelona, Spain (jtabernero@vhio.net). This podcast is conducted by Anna Berghoff, Department of Medicine, Medical University of Vienna, Austria.

Highlights from the Gastrointestinal Cancers Symposium Feb 17, 2016

Show notes

A critical review of key studies from the ASCO 2016 Gastrointestinal Cancers Symposium, held January 2016, is presented in this podcast. A number of tumor areas, including gastric, esophageal and colorectal cancers, are considered with an emphasis on recent developments in immunotherapy. Studies reviewed include the CheckMate-032 trial, which assessed the activity of the anti-PD-1 antibody nivolumab in patients with advanced gastric or gastroesophageal junction cancer, the KEYNOTE-028 trial, for which results of the esophageal carcinoma cohort treated with pembrolizumab were presented, and updated results of a trial considering PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers. Biomarkers are further considered in the Mavericc trial which sought to stratify metastatic colorectal cancer patients by ERCC1 in order to predict their response to platinum-based treatments. Neoadjuvant therapy was considered with the results of a study, from the Polish Colorectal Study Group, using neoadjuvant chemoradiation for fixed cT3 or cT4 rectal cancers, and the 5-year follow up results of the ACCORD 12 trial, which aimed to assess an increased radiation dose plus oxaliplatin versus standard radiotherapy of 45 Gy with concurrent capecitabine in rectal cancer.

These highlights are presented by Gerald W. Prager, Medical University of Vienna, Austria (gerald.prager@meduniwien.ac.at). The podcast is conducted by Anna Berghoff, Department of Medicine, Medical University of Vienna, Austria.

Highlights from San Antonio Breast Cancer Symposium 2015 Jan 12, 2016

Show notes

A critical review on the practice changing studies presented at the San Antonio Breast Cancer Symposium, held December 2015, is presented in this podcast. A number of areas, including neoadjuvant and adjuvant treatment, treatment of metastatic disease and the emergence of new biomarkers are addressed. Trials discussed include the WSG-ADAPT HER2+/HR+ phase II trial, which assessed 12-weeks of neoadjuvant TDM1 with or without endocrine therapy vs. trastuzumab+endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer, the CREATE-X study, which assessed adjuvant capecitabine in patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy, and the TH3RESA study, which investigated trastuzumab emtansine use in patients with previously treated HER2-positive metastatic breast cancer. Further, studies on new promising biomarkers such as the prognostic value of circulating tumor cells in follow up of early breast cancer patients after adjuvant chemotherapy are highlighted. Overall, the present podcast represents a comprehensive overview on some of the most important studies presented at the San Antonio Breast Cancer Symposium. These highlights are presented by Jacek Jassem, Department of Oncology and Radiotherapy, Medical University of Gdansk, Poland (jjassem@gumed.edu.pl). The podcast is conducted by Anna Berghoff, Department of Medicine, Medical University of Vienna, Austria.

Visit the ESMO Open website: http://esmoopen.bmj.com/content/1/1/e000043.

Related Podcasts